Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
100 participants
OBSERVATIONAL
2017-05-18
2023-01-24
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Lymphatic Morphology of Fontan Patients
NCT04163653
The Relationship Between Heart Function and Metabolism in HFpEF Patients
NCT05053256
Lymph Drainage in Heart Failure
NCT05240638
Tissue Factor Expression in Stage C Heart Failure
NCT00935740
Change of NLRP3 Inflammasome Expression Level, Symptoms, and Functional Status in HFpEF Patients Treated With ARNI
NCT04269057
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
OTHER
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Outpatient
Individuals undergoing clinically indicated Right Heart Catheterization.
No interventions assigned to this group
Inpatient
Individuals undergoing clinically indicated Right Heart Catheterization.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Use of medications which may alter lymphangiogenesis factor expression within 365 days
* Thalidomide, lenalidomide, pomalidomide
* Bevacizumab
* Any cytotoxic chemotherapy agents
* Pregnant
* Any potentially pregnant patient (based on age and gender) undergoes Beta Human chorionic gonadotropin testing as standard of care prior to any right heart catheterization.
* Active cancer within 365 days
* Diagnosis of familial or secondary lymphedema
* Treatment of active bacterial infection within 7 days
* Active inflammatory rheumatologic disease requiring anti-inflammatory therapy administration within 60 days
* Conditions
* Systemic lupus erythematosus
* Rheumatoid arthritis
* Scleroderma
* Inflammatory myositis
* Vasculitis
* Behcet's disease
18 Years
99 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Medical University of South Carolina
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Brian Houston, M.D.
Role: PRINCIPAL_INVESTIGATOR
Assistant Professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ralph H. Johnson VAMC
Charleston, South Carolina, United States
Medical University of South Carolina
Charleston, South Carolina, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Pro00062457
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.